Demystifying Bio-Techne: Insights From 4 Analyst Reviews

May 22, 2024 · Stay up to date on Bio-Techne analyst ratings. About Bio-Techne. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and …

$83
OFF

Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings)

2 weeks from now

Aug 13, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Bio-Techne, presenting an average target of $83.0, a high estimate of $95.00, and a low estimate …

nasdaq.com

$85
OFF

BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES

2 weeks from now

Demystifying Bio-Techne: Insights From 4 Analyst Reviews. 22 May 24. Analyst Ratings. Citigroup Downgrades Bio-Techne to Neutral, Announces $85 Price Target. 22 May 24. News, …

capedge.com

10%
OFF

What's The Opportunity In Bio-Techne? - Yahoo Finance

2 weeks from now

1 hour ago · Bio-Techne Corporation (NASDAQ:TECH) saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. The recent rally in share prices has …

yahoo.com

$95
OFF

Benchmark Reiterates Buy On Bio-Techne, Maintains $95 Price Target

2 weeks from now

Demystifying Bio-Techne: Insights From 4 Analyst Reviews. 22 May 24. Analyst Ratings. ... A Bio-Techne Company, Both Be Revoked, Advanced Cell Diagnostics' Infringement Claims Against …

capedge.com

$87.71
OFF

Demystifying Nasdaq: Insights From 14 Analyst Reviews

2 weeks from now

Jan 8, 2025 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.71, a high estimate of $98.00, and a low estimate of $80.00.

nasdaq.com

$11
OFF

Demystifying TELA Bio: Insights From 6 Analyst Reviews

2 weeks from now

Oct 4, 2024 · Analysts have set 12-month price targets for TELA Bio, revealing an average target of $11.0, a high estimate of $14.00, and a low estimate of $8.00.

nasdaq.com

FAQs about Demystifying Bio-Techne: Insights From 4 Analyst Reviews Coupon?

How has Bio-Techne (Tech) been rated by analysts?

Within the last quarter, Bio-Techne (NASDAQ:TECH) has observed the following analyst ratings: According to 4 analyst offering 12-month price targets in the last 3 months, Bio-Techne has an average price target of $94.5 with a high of $100.00 and a low of $88.00. Below is a summary of how these 4 analysts rated Bio-Techne over the past 3 months. ...

How do analysts evaluate Bio-Techne's market position?

Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Bio-Techne's future value. Comparing current and prior targets offers insights into analysts' evolving expectations. Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Techne's market position. ...

How many Bio-Techne reviews are there?

Share Your Experiences Glassdoor has 355 Bio-Techne reviews submitted anonymously by Bio-Techne employees. Read employee reviews and ratings on Glassdoor to decide if Bio-Techne is right for you. ...

Does Bio-Techne have a good debt-to-equity ratio?

Debt Management: With a below-average debt-to-equity ratio of 0.28, Bio-Techne adopts a prudent financial strategy, indicating a balanced approach to debt management. Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). ...

What is the average price target for Bio-Techne?

This current average reflects an increase of 8.54% from the previous average price target of $79.00. A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. ...

Is Bio-Techne a good stock to buy?

Return on Assets (ROA): Bio-Techne's ROA stands out, surpassing industry averages. With an impressive ROA of 1.8%, the company demonstrates effective utilization of assets and strong financial performance. Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average. ...